Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Nov 1 - Nov 6
The platform must offer secure chat, text reminders, video visits and short asynchronous updates
The master complaint filed in MDL 3094 asserts multiple causes of action against the defendants: Failure to warn of gastroparesis and persistent gastrointestinal injuries despite clinical trial data and post-market surveillance revealing these risks Negligent design and testing of GLP-1 receptor agonists without adequate safety protocols Breach of express and implied warranties regarding drug safety and efficacy Fraudulent concealment of known risks from regulatory agencies, physicians, and patients Violations of state consumer protection and unfair trade practices laws The lawsuit claims include negligent misrepresentation in marketing materials that emphasized benefits while minimizing serious adverse events The failure to warn allegations form the strongest foundation of these claims, as internal documents and regulatory timelines reveal a pattern of delayed safety communications to the medical community
Hgele, C., Friedel, E., Kienast, T
(2025, October) The SELECT trials prespecified analysis showed that semaglutide not only helped people with overweight or obesity and heart disease reduce cardiovascular risk, but that its benefits went beyond weight loss alone
As a result, the body relies on ketone bodies, a byproduct of ketosis, to energize brain, muscle, and tissue functions
.jpg)
